IP Library Granted Patent US 10,172,930
Granted Patent B2
US 10,172,930 · App. 15/144,265 · Granted Jan 8, 2019

Virus like particle purification

Inventors: Thomas S. Vedvick (Cambridge, MA); Bryan Steadman (Cambridge, MA); Charles Richardson (Cambridge, MA); Thomas R. Foubert (Cambridge, MA); Charles R. Petrie (Cambridge, MA)
Assignee: TAKEDA VACCINES, INC.
A61K39/12C07K1/18C07K14/005C12N7/00C12N2770/16023C12N2770/16034C12N2770/16051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,172,930
App. No.
15/144,265
Granted
Jan 8, 2019
Kind
B2
Abstract

Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.

Claims (11)

1. A composition comprising Norovirus genogroup II, genotype 4 (GII.4) virus-like particles (VLPs), wherein the composition is prepared by a method comprising contacting a solution containing said VLPs with at least one chromatographic material, wherein the at least one chromatographic material is an anion exchange chromatographic material, wherein the chromatographic materials used in the method do not comprise hydroxyapatite, and wherein the VLPs are present in the composition at a purity level of greater than about 90%.

2. The composition of claim 1 , wherein the anion exchange chromatographic material is a DEAE-Sepharose FF resin.

3. The composition of claim 1 , wherein at least one chromatographic material comprises a cation exchange chromatographic material.

4. The composition of claim 1 , wherein at least one chromatographic material comprises a hydrophobic interaction chromatographic material.

5. The composition of claim 1 , wherein the method further comprises a precipitation step.

6. The composition of claim 5 , wherein the precipitation step is a PEG precipitation step.

7. The composition of claim 6 , wherein the solution containing the VLPs is subjected to the PEG precipitation step prior to contacting the solution containing the VLPs with the anion exchange chromatographic material.

8. The composition of claim 1 , wherein the method further comprises an ultrafiltration and/or diafiltration step.

9. A pharmaceutical agent comprising the composition of claim 1 .

10. The pharmaceutical agent of claim 9 , wherein the pharmaceutical agent comprises a vaccine.

11. The composition of claim 1 , wherein the VLPs are present in the composition at a purity level of greater than about 95%.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2018
From: VEDVICK, THOMAS S.; STEADMAN, BRYAN; RICHARDSON, CHARLES; FOUBERT, THOMAS R.; PETRIE, CHARLES R.
To: LIGOCYTE PHARMACEUTICALS, INC.
Reel/Frame 045407/0022 →
MERGER Recorded Apr 2, 2018
From: INVIRAGEN, INC.; TAKEDA VACCINES (MONTANA), INC.
To: TAKEDA VACCINES, INC.
Reel/Frame 045407/0293 →
CHANGE OF NAME Recorded Apr 2, 2018
From: LIGOCYTE PHARMACEUTICALS, INC.
To: TAKEDA VACCINES (MONTANA), INC.
Reel/Frame 045803/0545 →
Continuity (4)
Division 13914331 · Jun 10, 2013
Continuation 12531248
Provisional Application 60906821 · Mar 14, 2007
Related Publication 20160317645A1 · Nov 3, 2016
Cited By (1)
US 12,286,456